Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

BACKGROUND: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in patients with T2DM <65 and ≥65 years of age. METHODS: Pooled data from 4 randomised, pl...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sinclair, Alan, Bode, Bruce, Harris, Stewart, Vijapurkar, Ujjwala, Mayer, Cristiana, Fung, Albert, Shaw, Wayne, Usiskin, Keith, Desai, Mehul, Meininger, Gary
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4021426/
https://ncbi.nlm.nih.gov/pubmed/24742013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6823-14-37
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky